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Abstract
Background: The International Collaboration on ADHD and 
Substance Abuse (ICASA) is a network of 28 centers from 16 
countries initiated to investigate the link between attention 
deficit-hyperactivity disorder (ADHD) and substance use dis-
order (SUD). In this article, we present the mission, the results 
of finished studies, and the current and future research proj-
ects of ICASA. Methods: During the past 10 years, 3 cross-
sectional studies were conducted: two International ADHD 
in Substance use disorders Prevalence (IASP-1 and IASP-2) 
studies, directed at the screening, diagnosis, and the preva-
lence of adult ADHD in treatment-seeking patients with 
SUD, and the Continuous performance test for ADHD in SUD 
Patients (CASP) study, testing a novel continuous perfor-
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
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mance test in SUD patients with and without adult ADHD. 
Recently, the prospective International Naturalistic Cohort 
Study of ADHD and Substance Use Disorders (INCAS) was 
initiated, directed at treatment provision and treatment out-
come in SUD patients with adult ADHD. Results: The IASP 
studies have shown that approximately 1 in 6 adult treat-
ment-seeking SUD patients also have ADHD. In addition, 
those SUD patients with adult ADHD compared to SUD pa-
tients without ADHD report more childhood trauma expo-
sure, slower infant development, greater problems control-
ling their temperament, and lower educational attainment. 
Comorbid patients also reported more risk-taking behavior, 
and a higher rate of other psychiatric disorders compared to 
SUD patients without ADHD. Screening, diagnosis, and treat-
ment of this patient group are possible even before absti-
nence has been achieved. The results of the CASP study are 
reported separately in this special issue. Conclusions: The 
ICASA research to date has demonstrated a high prevalence 
of comorbid ADHD and SUD, associated with elevated rates 
of additional comorbidities and risk factors for adverse out-
comes. More research is needed to find the best way to treat 
these patients, which is the main topic of the ongoing INCAS 
study. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Attention deficit-hyperactivity disorder (ADHD) and 
substance use disorder (SUD) often co-occur and have 
great clinical relevance [1–4]. However, adult ADHD is 
still under debate in the literature, especially in the context 
of SUD [5]. As a result, ADHD is often overlooked and 
undertreated among adults with SUD. In order to im-
prove the scientific basis for the screening, diagnosis, and 
treatment of ADHD-SUD comorbidity, the International 
Collaboration on ADHD and Substance Abuse (ICASA) 
was established as a foundation under Netherlands law in 
September 2010. Here, we describe the mission of the 
ICASA Foundation and summarize some of the findings 
of our first cross-sectional studies, including those from 
(1) the first International ADHD in Substance use disor-
ders Prevalence (IASP-1) study, (2) the second Interna-
tional ADHD in Substance use disorders Prevalence 
(IASP-2) study, and (3) the Continuous performance test 
for ADHD in SUD Patients (CASP) study. In addition, we 
provide a short description of other ICASA Network pub-
lications and the study design of ICASA’s first ongoing 
prospective study: the International Naturalistic Cohort 
Study of ADHD and Substance Use Disorders (INCAS).
ICASA Foundation’s Mission
The ICASA Foundation’s mission is “to contribute to a 
substantial decrease in the proportion of ADHD patients 
developing an addiction/substance use disorder and to sub-
stantially improve the detection, diagnosis and treatment 
of patients having both ADHD and SUD.” ICASA strives 
to achieve this by performing and coordinating high-qual-
ity epidemiological clinical research. The ICASA organi-
zation consists of the ICASA board of 6 members, a re-
search network currently consisting of 54 participants, 
representing over twenty addiction and mental health in-
stitutes from 16 different countries, and the ICASA re-
search office, positioned at the Radboud University Med-
ical Centre (Radboudumc) and the Nijmegen Institute for 
Scientist-Practitioners in Addiction in Nijmegen, The 
Netherlands. Further information on the ICASA Founda-
tion can be found at www.adhdandsubstanceabuse.org.
First International ADHD in Substance Use Disorders 
Prevalence Study
Background/Study Design
In order to learn more about the magnitude of the re-
lationship between ADHD and SUD, a systematic review 
and meta-analysis was performed of existing prevalence 
studies. In their meta-analysis, van Emmerik-van Oort-
merssen et al. [1] calculated that the average percentage 
of ADHD cases in SUD patients based on 29 included 
studies was 23.1%. As these results were based mainly on 
US studies using different sampling and assessment pro-
cedures, the ICASA network decided to conduct the 
IASP-1 study[6], a cross-sectional study including 3,578 
treatment-seeking SUD patients from 47 sites in 10 coun-
tries (Norway, Sweden, The Netherlands, Belgium, 
France, Spain, Switzerland, Hungary, Australia, and the 
USA) using the Adult ADHD Self-Report Scale (ASRS) as 
a screener for ADHD, the Conners’ Adult ADHD Diag-
nostic Interview for DSM-IV for the diagnosis of adult 
ADHD, the Mini-International Neuropsychiatric Inter-
view (MINI-Plus) for the diagnosis of SUD and other 
DSM-IV Axis I disorders, and the Structured Clinical In-
terview for DSM-IV Axis II Disorders for the diagnosis of 
borderline personality disorder.
Main Findings
In this study, the prevalence of adult ADHD in treat-
ment-seeking SUD patients ranged from 7.6% (CI 95%: 
4.1–11.1) in the Hungarian sample to 32.6% (CI 95%: 
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26.4–38.8) in the Norwegian sample. Moreover, we ob-
served higher prevalence rates for drug-dependent com-
pared to alcohol-dependent patients, and higher preva-
lence rates in outpatient compared to inpatient samples 
[7]. In all participating sites, adult ADHD was more prev-
alent than the 2.5% ADHD prevalence in adults in the 
general population as presented by Simon et al. [8].
To establish the validity of the ASRS 6-item version, 
for adult ADHD in treatment-seeking SUD patients, van 
de Glind et al. [9] calculated sensitivity and specificity of 
the 6-item version of the ASRS with the CAADID as ex-
ternal criterion at intake and 1–2 weeks later with similar 
results at both time points (sensitivity = 0.84, 95% CI: 
0.76–0.88; specificity = 0.66, 95% CI: 0.63–0.69). Since 
there is no specific instrument to diagnose ADHD in 
SUD patients, we assessed the validity of the ADHD mod-
ule of the MINI-Plus in SUD patients, using the CAADID 
as external criterion (Ramos Quiroga, under review). 
Sensitivity of the MINI-Plus ADHD module was 74%, 
specificity was 91%, and Kappa was 0.60.
Taken together, these findings show that adult ADHD 
is highly prevalent in treatment-seeking SUD patients in 
the USA, Europe, and Australia, and patients can be ef-
fectively screened at intake, even during active substance 
use. Therefore, every patient in an addiction treatment 
center should be screened at intake for the presence of a 
comorbid diagnosis of adult ADHD.
Additional Findings
In their report on comorbidity in the IASP-1 study, 
Van Emmerik-van Oortmerssen et al. [10] showed that 
antisocial personality disorder, borderline personality 
disorder, and mood disorders were more prevalent in 
SUD patients with adult ADHD (SUD + ADHD) com-
pared to SUD patients without adult ADHD (SUD-AD-
HD). Seventy-five percent of the SUD + ADHD patients 
had at least 1 additional comorbid disorder compared to 
37% of SUD-ADHD patients. Furthermore, Wapp et al. 
[11] showed that SUD patients with BPD in the IASP-1 
study had a significantly higher prevalence of comorbid 
adult ADHD (OR = 3.16), compared to SUD patients 
without BPD. Kaye et al. [5] reported that in the IASP-1 
study, childhood ADHD persisted into adulthood in 
72.8% of all cases. ADHD persistence was significantly 
associated with a family history of ADHD and the pres-
ence of conduct disorder and antisocial personality disor-
der.
Based on data from the IASP-1 study, Konstenius et al. 
[12] reported increased rates of ADHD (19.5%) in SUD 
patients with childhood trauma exposure (including sex-
ual, physical, and emotional abuse; neglect; and family 
violence), compared to those without trauma (8.5%). In 
addition, Skutle et al. [13] showed that in the IASP-1 
study, SUD with ADHD patients had a significantly slow-
er infant development than SUD without ADHD pa-
tients, more problems controlling their temperament, 
and lower educational attainment.
Based on the Australian subsample of the IASP-1 
study, Young et al. [14] provided evidence for increased 
drug dependence and chronicity in treatment-seeking 
SUD patients with a positive screen for ADHD. Based on 
the same Australian subsample, using additional ques-
tionnaires on risk-taking behavior, Kaye et al. [15] showed 
that ADHD symptom status was independently associ-
ated with a greater overall number of driving offences, a 
higher frequency of driving without a seatbelt, a greater 
likelihood of having driven without a valid license, more 
at-fault accidents, and having one’s license disqualified at 
the time of interview.
Other ICASA Network Publications
Reviews on ADHD and SUD
In their review of the literature, Slobodin and Crunelle 
[16] discuss the role of sociocultural aspects in the link 
between ADHD and SUD, including cultural factors such 
as perceptions of normal and abnormal behavior, behav-
ioral norms, attitudes and knowledge about mental health 
problems, and factors related to the utilization of mental 
health services among certain populations. They con-
clude that a better understanding of the role of culture 
and context in the ADHD-SUD link may not only shed 
light on the large variation in the prevalence of ADHD in 
SUD patients across cultures but also assist in early detec-
tion of ADHD in SUD patients.
Slobodin et al. [17] also reviewed the literature about 
the role of different aspects of impulsivity (disinhibition, 
impulsive choice, and sensation seeking) as independent 
risk factors for SUD in patients with ADHD. They con-
cluded that different impulsivity constructs operate inde-
pendently and interact with each other to affect adult 
risk-taking behavior and SUD in patients with childhood 
ADHD [17].
Consensus Statement on Screening, Diagnosis, and 
Treatment of ADHD in SUD Adult Patients
To inform professionals working with patients suffer-
ing from SUD and (possible) adult ADHD, ICASA re-
viewed the existing scientific literature on screening, di-
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agnosis, and treatment of SUD patients with adult ADHD 
and synthesized a consensus guide for clinical practice. In 
this consensus statement, Crunelle et al. [18] highlight the 
importance of screening for adult ADHD in all SUD pop-
ulations and suggest how screening and diagnostic pro-
cedures can be carried out. Finally, the currently available 
evidence for treatment of ADHD in SUD patients was 
also summarized [18]. To serve more professionals, the 
consensus statement has now been translated into Dutch 
[19] and German [20], and we are working on a French 
and Swedish version.
Ongoing Projects
ICASA collected DNA in a subsample of the IASP-1 
study and these DNA data are currently being analyzed. 
Furthermore, the IASP study was expanded to Puerto 
Rico and South Africa (IASP-2). Details on study design 
and some of the data from the IASP-2 study are presented 
in this special issue of European Addiction Research [21, 
22]. In the CASP study, we collected data with a novel 
continuous performance test [23] in SUD patients with 
and without ADHD. Results from this study can be found 
in this special issue of European Addiction Research [24].
Finally, we intend to merge our data of IASP-1 and 
IASP-2 studies with other datasets in order to learn more 
about SUD patients with and without ADHD. An exam-
ple is the pilot study by Regnart et al. [25], investigating 
the ASRS in a South African sample of treatment-seeking 
SUD patients. In this study, 43.3% of the SUD patients 
screened positive for ADHD, which is very similar to the 
40.9% screen positives in the IASP-1 study [6].
New ICASA Study: INCAS
Background
There is a lack of evidence-based treatment options for 
SUD patients with comorbid ADHD due to limited re-
search in this population [18]. Although some random-
ized controlled trials have investigated specific pharma-
cological treatments in selected populations, they provide 
limited data on the natural course of the disorders and 
predictors of treatment efficacy in routine clinical set-
tings [2, 3].
Therefore, INCAS aims to investigate the treatment 
modalities provided to treatment-seeking SUD patients 
with comorbid ADHD, and to identify predictors for suc-
cessful treatment outcomes, as measured by retention, 
substance use, and ADHD symptoms. In addition, the 
tolerability and safety profile of different pharmacologi-
cal treatments will be recorded.
Study Design
This prospective international cohort study has a nat-
uralistic observational design, with a recruitment target 
of 600 treatment-seeking adult SUD patients with comor-
bid adult ADHD. Patients are currently (May 2020) re-
cruited at 23 different sites in Belgium, Germany, Hun-
gary, The Netherlands, Spain, Sweden, Switzerland, and 
the USA, whereas recruitment will start soon in Australia 
and France. Data are collected from patient files, inter-
views, and self-rating scales at inclusion, after 4 weeks, 3 
months, and 9 months.
Each participating treatment center invites consecu-
tive patients with ADHD and comorbid SUD to partici-
pate in the study. The planned recruitment period is from 
July 2017–June 2021.
Methods
The primary outcomes are retention, ADHD symp-
toms, and substance use at 3 months’ follow-up. At 4 
weeks, 3 months, and 9 months, ADHD symptoms are 
measured by the ASRS and substance use as number of 
days with heavy alcohol use and/or days with illicit drug 
use during the last 30 days before assessment using the 
Timeline Followback method. In addition, overall func-
tioning will be assessed with the Clinical Global Impres-
sion Severity/Improvement scale and the EuroQol-5D.
Information on provided treatment, such as psycho-
logical and pharmacological treatments, including stimu-
lant dosing, will be assessed continuously. At baseline and 
follow-up visits, the following predictors of treatment 
provision and treatment outcome are assessed through 
information collected via interviews and patient files: so-
ciodemographic data (housing, employment, level of ed-
ucation, etc.), age, gender, previous treatments, other 
psychiatric comorbidities, adverse events (in relation to 
ADHD medications), and misuse/diversion of prescrip-
tive drugs (see Table 1).
Conclusions
ICASA is an active group of clinicians and clinical re-
searchers that conducted important cross-sectional stud-
ies on adult ADHD in treatment-seeking SUD patients 
(IASP-1, IASP-2, and CASP). Currently, ICASA is exe-
cuting its first prospective study on treatment provision 
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and treatment outcome in treatment-seeking SUD pa-
tients with adult ADHD (INCAS).
So far, our review/meta-analysis [1] and the results of 
the IASP-1 study [5–7, 9, 10, 12–15] show that approxi-
mately 1 in 6 SUD patients meet criteria for adult ADHD. 
The results also show that compared to SUD patients 
without ADHD, these patients report more childhood 
trauma exposure [12], slower infant development, greater 
problems controlling their temperament, and lower edu-
cational attainment. Moreover, this group of patients 
shows more risk-taking behavior [15] and higher rates of 
other psychiatric disorders, including antisocial personal-
ity disorder, major depression, borderline personality dis-
order, and hypomanic episode [10]. Finally, our interna-
tional consensus statement underscores that screening, 
diagnosis, and treatment of this patient group is well pos-
sible [18].
Various aspects regarding the etiology, risk profile, 
neurobiology, genetics, development, screening, diagno-
sis, and treatment of ADHD-SUD comorbidity need on-
going attention of both clinicians in the field and re-
searchers in the scientific community. Our prospective 
cohort study, INCAS, addresses some of these topics and 
will provide unique data on the natural course of the dis-
orders and on predictors of treatment efficacy in a routine 
clinical setting. ICASA brings together professionals with 
wide-ranging expertise in the fields of ADHD and SUD 
and is, therefore, ideally positioned to provide answers to 
at least some of the remaining questions.
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Table 1. Overview of administrated self-rating scales in the INCAS study
Instrument Items Administrated at
Expanded ASRS 36 Baseline, 3 and 9 months
EQ-5D 5 Baseline, 3 and 9 months
Self-efficacy 3 Baseline, 3 and 9 months
Fagerstrom test for nicotine dependence 6 Baseline, 3 and 9 months
Assessment of craving 3 Baseline, 3 and 9 months
Sensitivity to punishment and sensitivity to reward questionnaire 17 Baseline and 3 months
Difficulties in emotion regulation-16 16 Baseline, 3 and 9 months
Religious salience 3 Baseline, 3 and 9 months
Questionnaire on anger and agression 8 Baseline
INCAS, International Naturalistic Cohort Study of ADHD and Substance Use Disorders; ASRS, Adult ADHD 
Self-Report Scale; EQ-5D, EuroQol-5D.
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